COLUMBUS, Ohio — Governor Mike DeWine and Ohio Department of Health (ODH) Director Dr. Bruce Vanderhoff announced a significant enhancement to Ohio’s newborn screening capabilities for cystic fibrosis, aiming to include screening for the maximum number of mutations possible through laboratory testing.
During a briefing with the Newborn Screening Advisory Council, ODH revealed plans to expand screening to encompass rare mutations of cystic fibrosis. This initiative, slated to commence this fall, positions Ohio among a select few states conducting comprehensive screening for the broadest range of mutations associated with the condition.
Governor DeWine emphasized the importance of early detection and intervention in managing cystic fibrosis. “Prompt diagnosis and early treatment are critical to ensuring children with cystic fibrosis can lead healthier lives,” stated Governor DeWine. “By broadening our screening capabilities to detect even the rarest forms of this disease at birth, Ohio is offering every child the best chance for optimal health outcomes.”
Cystic fibrosis is a genetic disorder characterized by the production of thick, sticky mucus that can obstruct organs such as the lungs and digestive system. Early diagnosis through newborn screening allows for timely initiation of treatment, which can mitigate lifelong health complications associated with the disease.
Currently, Ohio mandates newborn screening for 41 different conditions, including cystic fibrosis, for all newborns in the state. Screening analysis is conducted at ODH’s Public Health Laboratory, contributing to improved health outcomes for nearly 300 infants annually.
“Expanding our screening protocols for cystic fibrosis means more families will have early access to crucial treatment plans,” remarked Dr. Vanderhoff. “This proactive approach is vital in addressing the challenges posed by cystic fibrosis and enhancing the quality of life for affected children.”
The implementation of expanded screening is scheduled to begin in the coming months. Initially, ODH will collaborate with an external laboratory to conduct the additional screenings while concurrently training its own laboratory personnel. The long-term objective is to transition these expanded screening capabilities entirely in-house.
The enhancement underscores Ohio’s commitment to leveraging medical advancements and early intervention strategies to improve health outcomes for its youngest residents.
